Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Quote | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Last: | $146.80 |
---|---|
Change Percent: | 0.14% |
Open: | $145.89 |
Close: | $146.80 |
High: | $148.02 |
Low: | $144.35 |
Volume: | 744,756 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
2024-07-19 09:56:40 ET Summary Takeda Pharmaceutical Company Limited showed signs of improvement despite revenue declines in oncology and neurosciences, thanks to gains in gastrointestinal and inflammation sectors and strategic leadership changes. The company's “returning t...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
Message Board Posts | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Subject | By | Source | When |
---|---|---|---|
https://finance.yahoo.com/m/ac97a7cc-59a6-39e8-8438-16d26de87a27/voyager%2C-neur | TheFinalCD | investorshub | 01/09/2023 7:23:31 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences Reports Third Quarter 2022 Financial Result | whytestocks | investorshangout | 11/01/2022 3:55:56 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences Presents INGREZZA (valbenazine) Data on Sus | whytestocks | investorshangout | 09/19/2022 12:45:51 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences to Present Study Findings on Evolving Tardi | whytestocks | investorshangout | 09/15/2022 7:35:48 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences to Present New INGREZZA (valbenazine) and O | whytestocks | investorshangout | 09/10/2021 7:05:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $170.00 for NBIX on 2024-07-12 08:10:00. The adjusted price target was set to $170.00. At the time of the announcement, NBIX was trading at $146.5. The overall price target consensus is at $...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...